CELU PRESS-RELEASE SEC Filing Analysis

Final — all horizons settled through T+60d

CELU ▼ -31.34% at T+60d

NEUTRAL call ✗ call lost -31.34% · α vs SPY -42.04% · entry $1.27 → $0.8720

Last close $0.7130 (close Jun 12) · -43.86% from $1.27 entry

Entry anchored
Mar 11, 03:59 PM ET
via Databento tick

T+1d

-3.94%

call -3.94% · α -3.34%

$1.22

settled 3mo ago

T+5d

0.00%

call 0.00% · α +0.98%

$1.27

settled 3mo ago

T+20d

0.00%

call 0.00% · α -1.98%

$1.27

settled 2mo ago

T+60d

-31.34%

call -31.34% · α -42.04%

$0.8720

settled 7d ago

Price Chart

Loading chart...

Executive Summary

Celularity Inc. announced a strategic commercialization partnership with NEXGEL, Inc., licensing its established biomaterial products and pipeline programs for wound care and orthopedics. Celularity will serve as the exclusive manufacturer, leveraging its FDA-compliant facility in New Jersey, while NEXGEL takes responsibility for commercialization. The deal is expected to close by April 15, 2026, subject to customary conditions.

Actionable Insight

Monitor for future disclosures on financial terms, manufacturing volume commitments, or regulatory progress of licensed products; the partnership may improve Celularity’s capital efficiency but lacks near-term financial visibility.

Key Facts

Celularity licensed commercial products (Biovance, Natalin, Acelagraft, etc.) and pipeline programs (SPARK, FUSE, ORCHID) to NEXGEL.
Celularity will be the exclusive manufacturer at its Florham Park, NJ facility.
The transaction is expected to close by April 15, 2026, subject to customary closing conditions.
No financial terms (e.g., upfront payment, milestone amounts, royalty rates) were disclosed in the press release.
Management highlights strategic focus on contract manufacturing and capital efficiency.

Financial Impact

Potential future revenue from manufacturing, milestones, and royalties — magnitude unknown due to lack of disclosed financials

revenuemanufacturing_volumecash_flow

Risk Factors

Transaction may not close on time or at all due to unmet conditions.
No guarantee of meaningful manufacturing revenue if NEXGEL fails to commercialize products successfully.
Lack of disclosed financial terms limits ability to assess true economic value to Celularity.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3254647

5 reports for CELU

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CELU — sortable, filterable
	Type				Now
May 29, 2026 16d ago	Press Release BEARISH ★ 6/10	$1.07 $0.8720	▲ +18.50%	▲ +15.75%	$0.7130 (+33.36%)
Apr 21, 2026 7w ago	Press Release NEUTRAL ★ 5/10	$1.22 $1.04	▼ −14.75%	▼ −15.84%	$0.7130 (−41.56%)
Apr 17, 2026 8w ago	Press Release BEARISH ★ 6/10	$1.24 $0.9900	▲ +20.16%	▲ +21.07%	$0.7130 (+42.50%)
Mar 12, 2026 13w ago	Press Release MIXED ★ 6/10	$1.27 $1.27	· 0.00%	▲ +0.98%	$0.7130 (−43.86%)
Mar 5, 2026 14w ago	8-K NEUTRAL ★ 3/10	$1.21 $1.22	▲ +0.83%	▲ +2.35%	$0.7130 (−41.07%)

US Market Status

Market Closed — Opens in 4h 9m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access